Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Anticancer Bioscience logo — Applying our synthetic lethality expertise for better cancer...

Anticancer Bioscience

Applying our synthetic lethality expertise for better cancer therapies

Founded 2016 China Chengdu, China 17 employees Seed Total: $200.15M Biotechnology, Health Care +3

General Information

Company Name Anticancer Bioscience
Founded Year 2016
Location China Chengdu, China
Employees 17
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Anticancer Bioscience. To contact Anticancer Bioscience, visit anticancerbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Anticancer Bioscience compare?

A PDF of Anticancer Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Anticancer Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Anticancer Bioscience

Anticancer Bioscience (ACB) is a precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, the United Kingdom, and the United States. The company's focus lies in developing synthetic lethal therapies that address unmet medical needs in the field of Biotechnology, Health Care, Health and Wellness, Life Sciences, and the Pharmaceutical industry. At the forefront of ACB's offerings are their synthetic lethal therapies for cancer. Founded in 2016 by experts in identifying and exploiting cancer vulnerabilities, ACB has gathered a team of talented scientists dedicated to developing safe, effective, and broad-spectrum targeted therapies for cancers that are currently inaccessible or have become refractory to existing therapy. The company recently secured a CNY68.40M Seed Round investment on 14 October 2021 from 3 Rivers Capital, LLC. ACB's mission and dedication to developing innovative drugs in the oncology space positions it as a promising investment opportunity for Venture Capitalists seeking to support advancements in cancer treatment. For more information about ACB's pipeline of drugs and technology platforms, as well as potential partnership and employment opportunities, visit www.anticancerbio.com.

Business keywords: Precision Therapeutics, Synthetic Lethal Therapies, Oncology Research, Cancer Vulnerabilities, Genetic Perturbations, Medicinal Chemistry, Drug Development, Targeted Therapies, Cancer Treatment Innovation, Global Research and Development, Employment Opportunities, Equal Opportunity Employer

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round CNY68.40M 1
3 Rivers Capital, LLC
3 Rivers Capital, LLC
14 Oct 2021
Seed Round CNY63.00M -
08 Feb 2021
Seed Round CNY68.75M -
01 Jan 2020

Anticancer Bioscience Alternatives & Competitors

View All Alternatives
Anticancer Bioscience vs
Tavros Therapeutics
Tavros Therapeutics United States

Leading the new frontier of targeted cancer therapies exploiting tumors’ genetic vulnerabilities.

Acquired
22 employees
Biotechnology, Health Care
Anticancer Bioscience vs
Scorpion Therapeutics
Scorpion Therapeutics

Pioneering the Next Generation of Precision Oncology

Series C
16 employees
Biotechnology, Health Care
Anticancer Bioscience vs
Synnovation Therapeutics
Synnovation Therapeutics United States

A precision oncology company focused on small molecule therapies optimized to target key driver mech...

Series A
52 employees
Biotechnology, Health Care
Also compare with: Anticancer Bioscience vs Volastra Therapeutics Volastra Therapeutics View all alternatives

FAQ About Anticancer Bioscience

Applying our synthetic lethality expertise for better cancer therapies
Anticancer Bioscience was founded in 2016.
Anticancer Bioscience is headquartered in Chengdu, China.
Anticancer Bioscience operates in Biotechnology, Health Care, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on Precision Therapeutics, Synthetic Lethal Therapies, Oncology Research and Cancer Vulnerabilities.
Anticancer Bioscience has approximately 17 employees.
Anticancer Bioscience has completed 3 funding rounds, raising a total of $200.15M. The latest funding stage is Seed.
Top alternatives and competitors to Anticancer Bioscience include Tavros Therapeutics, Scorpion Therapeutics, Synnovation Therapeutics, Xcovery Holdings, Inc., Volastra Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Anticancer Bioscience and Tavros Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Anticancer Bioscience, https://bouncewatch.com/company/anticancer-bioscience, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout